Back to Search
Start Over
Axitinib as a third or further line of treatment in renal cancer. A single institution experience
- Source :
- BMC Urology, BMC Urology, Vol 20, Iss 1, Pp 1-8 (2020)
- Publication Year :
- 2020
- Publisher :
- Research Square Platform LLC, 2020.
-
Abstract
- Background Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Methods Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included. Results Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events. Conclusions Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
Axitinib
medicine.drug_class
Urology
lcsh:RC870-923
Tyrosine-kinase inhibitor
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
Internal medicine
medicine
Humans
Long responders
Adverse effect
Carcinoma, Renal Cell
Protein Kinase Inhibitors
Aged
Retrospective Studies
business.industry
Cancer
Retrospective cohort study
mRCC
General Medicine
Middle Aged
lcsh:Diseases of the genitourinary system. Urology
medicine.disease
Kidney Neoplasms
Regimen
030104 developmental biology
TKIs
Reproductive Medicine
beyond second line
030220 oncology & carcinogenesis
Female
business
Kidney cancer
Research Article
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- BMC Urology, BMC Urology, Vol 20, Iss 1, Pp 1-8 (2020)
- Accession number :
- edsair.doi.dedup.....9efbcc072423bd30118081037e901816